[Plasma insulin, glucose and lipid levels, and their relations with corrected TIMI frame count in patients with slow coronary flow]
- PMID: 12967888
[Plasma insulin, glucose and lipid levels, and their relations with corrected TIMI frame count in patients with slow coronary flow]
Abstract
Objective: High baseline insulin and glucose levels and presence of accompanying dyslipidemia, which are considered in the pathogenesis of metabolic syndrome X, were also observed in patients with cardiac syndrome X, which is similar to metabolic syndrome X in many aspects. In this study we aimed to compare serum insulin, glucose and lipid levels in patients with coronary slow flow which is hypothesized as a subgroup of cardiac syndrome X with those of healthy subjects and determine the relation of corrected TIMI frame count (cTFC) with these levels.
Methods: Forty-six patients with normal epicardial coronary arteries but determined as coronary slow flow in coronary angiography performed because of chest pain and 16 healthy subjects having normal coronary arteries but without coronary slow flow were included in this study. Maximal exercise stress test according to Bruce protocol was performed in all patients. Baseline serum insulin, glucose and lipid levels were measured from venous blood samples of patients in both groups. TIMI 'frame count' method was used for diagnosis of coronary slow flow. The relationship between the degree of coronary slow flow and serum insulin, glucose and lipid levels was investigated.
Results: Exercise stress test results of both groups were considered as negative regarding ischemia. There were no differences between 2 groups in serum insulin, glucose and lipid levels. (p>0.05). No relationship were determined by correlations analysis between serum insulin, glucose and lipid levels and corrected TIMI frame count.
Conclusion: Normal values of insulin, glucose and lipid levels in patients with coronary slow flow and lack of their relation with cTFC support the opinion that coronary slow flow is a separate from the cardiac syndrome X clinical entity.
Comment in
-
[Slow coronary flow].Anadolu Kardiyol Derg. 2003 Sep;3(3):227-9. Anadolu Kardiyol Derg. 2003. PMID: 12967889 Turkish. No abstract available.
Similar articles
-
Assessment of coronary blood flow in hypertrophic cardiomyopathy using thrombolysis in myocardial infarction frame count method.J Invasive Cardiol. 2005 Feb;17(2):73-6. J Invasive Cardiol. 2005. PMID: 15687528
-
Clinical and coronary angiographic characteristics of patients with coronary slow flow.Acta Cardiol. 2008 Oct;63(5):579-84. doi: 10.2143/AC.63.5.2033224. Acta Cardiol. 2008. PMID: 19014000
-
Impaired coronary blood flow in patients with metabolic syndrome: documented by Thrombolysis in Myocardial Infarction (TIMI) frame count method.Am Heart J. 2004 Nov;148(5):789-94. doi: 10.1016/j.ahj.2004.05.016. Am Heart J. 2004. PMID: 15523308
-
Use of the TIMI frame count in the assessment of coronary artery blood flow and microvascular function over the past 15 years.J Thromb Thrombolysis. 2009 Apr;27(3):316-28. doi: 10.1007/s11239-008-0220-3. Epub 2008 Apr 20. J Thromb Thrombolysis. 2009. PMID: 18425623 Review.
-
New perspectives in slow coronary flow: a review and update.Panminerva Med. 2025 Jun;67(2):72-86. doi: 10.23736/S0031-0808.25.05311-X. Epub 2025 Apr 23. Panminerva Med. 2025. PMID: 40265957 Review.
Cited by
-
Thrombin activatable fibrinolysis inhibitor : its role in slow coronary flow.Herz. 2014 Dec;39(8):993-1000. doi: 10.1007/s00059-013-3942-8. Epub 2013 Sep 27. Herz. 2014. PMID: 24068025
-
The relationship between triglyceride/high-density lipoprotein cholesterol ratio and coronary slow-flow phenomenon.Int J Cardiovasc Imaging. 2022 Jan;38(1):5-13. doi: 10.1007/s10554-021-02387-w. Epub 2021 Aug 28. Int J Cardiovasc Imaging. 2022. PMID: 34453654
MeSH terms
Substances
LinkOut - more resources
Medical